COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss

Crabb, SJ, Martin, K, Abab, J et al. (21 more authors) (2017) COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss. European Journal of Cancer, 87. pp. 75-83. ISSN 0959-8049

Abstract

Metadata

Authors/Creators:
  • Crabb, SJ
  • Martin, K
  • Abab, J
  • Ratcliffe, I
  • Thornton, R
  • Lineton, B
  • Ellis, M
  • Moody, R
  • Stanton, L
  • Galanopoulou, A
  • Maishman, T
  • Geldart, T
  • Bayne, M
  • Davies, J
  • Lamb, C
  • Popat, S
  • Joffe, JK
  • Nutting, C
  • Chester, J
  • Hartley, A
  • Thomas, G
  • Ottensmeier, C
  • Huddart, R
  • King, E
Copyright, Publisher and Additional Information: © 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Cisplatin; Chemotherapy; Aspirin; Ototoxicity; Hearing
Dates:
  • Published: December 2017
  • Accepted: 25 September 2017
  • Published (online): 10 November 2017
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Clinical Cancer Research (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 14 Nov 2017 13:21
Last Modified: 14 Nov 2017 13:21
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/j.ejca.2017.09.033

Share / Export

Statistics